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Abstract  Contrast-induced  acute  kidney  injury  is  the  third  leading  cause  of  intrahospital  acute
kidney disease,  accounting  for  11%  of  all  cases.  It  is  associated  with  a  worse  prognosis  on  the
short- and  long-term,  as  well  as  with  extended  hospital  stay  and  increase  in  health-care  costs.
As the  number  of  diagnostic  and  interventional  angiographies  and  computerized  tomography
increases  in  clinical  practice  and  higher  doses  of  contrast  media  are  administered  to  sicker  and
older patients,  contrast-induced  acute  kidney  injury  is  an  increasing  problem.  Contrast-induced
acute kidney  injury  is  a  unique  form  of  acute  kidney  injury  in  that  its  risk  factors  are  known
and its  timing  predictable.  This  makes  room  for  the  implementation  of  prophylactic  measures
in patients  at  risk.
Several  articles  were  searched  in  nephrology  journals  (‘‘American  Journal  of  Kidney  Dis-
ease’’, ‘‘Journal  of  the  American  Society  of  Nephrology’’,  ‘‘Clinical  Journal  of  the  American
Society of  Nephrology’’,  ‘‘Kidney  International’’  and  ‘‘Nephrology  Dialysis  Transplantation’’)
for a  global  view  on  contrast-induced  acute  kidney  injury  and  prophylactic  strategies.  Subse-
quently, individual  searches  were  made  on  MEDLINE® database  for  randomized  controlled  trials
and meta-analyses  on  each  prophylactic  strategy  encountered.
Several  approaches  to  contrast-induced  acute  kidney  injury  prevention  have  been  reported,
of which  vigorous  hydration  and  the  use  of  non-ionic  contrast  media  are  the  most  important.
The administration  of  oral  N-acetylcysteine  is  also  a  popular  strategy  in  virtue  of  its  favorable
risk/beneﬁt  proﬁle.  Statins  have  also  been  reported  as  protective  against  contrast-induced
acute kidney  injury.  The  authors  review  the  disease  and  studied  prophylactic  interventions,
presenting  a  practical  approach  to  the  prevention  of  contrast-induced  acute  kidney  injury.
© 2015  Sociedade  Portuguesa  de  Angiologia  e  Cirurgia  Vascular.  Published  by  Else-
vier España,  S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail address: ritagouveia18@msn.com (R. Gouveia).
ttp://dx.doi.org/10.1016/j.ancv.2015.01.009
646-706X/© 2015 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Published by Elsevier España, S.L.U. This is an open access article
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contrast-induced  acute  kidney  injury  --  A  review  focusing  on  prophylactic  strategies  69
PALAVRAS-CHAVE
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computorizada
Lesão  renal  aguda  induzida  pelo  contraste  --  Uma  revisão  focando  as  estratégias
proﬁlácticas
Resumo  A  lesão  renal  aguda  associada  ao  uso  de  contraste  iodado  é  a  3a causa  mais  frequente
de lesão  renal  aguda  intra-hospitalar,  sendo  responsável  por  11%  de  todos  os  casos.  A  lesão
renal aguda  induzida  pelo  contraste  associa-se  a  pior  prognóstico  a  curto  e  longo  prazo,  bem
como a  maior  durac¸ão  do  internamento  hospitalar  e  maiores  custos.  À  medida  que  o  número
de angiograﬁas  diagnósticas  e  terapêuticas  e  tomograﬁas  computorizadas  aumenta  na  prática
clínica e  que  maiores  doses  de  contraste  são  administradas  a  doentes  com  idades  mais  avanc¸adas
e maior  número  de  co-morbilidades,  a  lesão  renal  aguda  induzida  pelo  contraste  é  um  problema
crescente.  A  lesão  renal  aguda  induzida  pelo  contraste  é  uma  forma  única  de  lesão  renal  aguda
na medida  em  que  os  factores  de  risco  são  conhecidos  e  é  previsível  no  tempo.  Assim,  torna-se
possível  a  implementac¸ão  de  medidas  proﬁlácticas  nos  doentes  em  risco.
Os autores  pesquisaram  artigos  sobre  lesão  renal  aguda  induzida  pelo  contraste  e  estratégias
proﬁlácticas  em  diversas  revistas  nefrológicas  (‘‘American  Journal  of  Kidney  Disease’’,  ‘‘Journal
of the  American  Society  of  Nephrology’’,  ‘‘Clinical  Journal  of  the  American  Society  of  Nephrol-
ogy’’, ‘‘Kidney  International’’  and  ‘‘Nephrology  Dialysis  Transplantation’’).  Posteriormente,
foram efectuadas  pesquisas  individuais  na  base  de  dados  MEDLINE® de  estudos  randomizados
controlados  e  metanálises  para  cada  estratégia  proﬁláctica  encontrada.
Várias abordagens  na  prevenc¸ão  da  lesão  renal  aguda  induzida  pelo  contraste  têm  sido
descritas, das  quais  a  hidratac¸ão  vigorosa  e  o  uso  e  contraste  iodado  não-iónico  são  as  mais
importantes.  A  administrac¸ão  de  N-acetilcisteína  oral  é  também  uma  estratégia  popular  em
virtude do  seu  favorável  perﬁl  de  risco/benefício.  As  estatinas  têm  vindo  a  ser  descritas  como
protectoras  contra  a  lesão  renal  aguda  induzida  pelo  contraste.  Os  autores  fazem  uma  revisão
da patologia  e  das  intervenc¸ões  proﬁlácticas  testadas,  propondo  uma  estratégia  preventiva.
© 2015  Sociedade  Portuguesa  de  Angiologia  e  Cirurgia  Vascular.  Publicado  por  Else-
vier España,  S.L.U.  Este  é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of  acute  kidney  injury  by  the  Acute  Kidney  Injury  NetworkIntroduction
Contrast-induced  acute  kidney  injury  (CI-AKI)  is  a  form  of
AKI  that  occurs  after  the  exposure  to  intravascular  iodi-
nated  contrast  media.1,2 It  is  responsible  for  11%  of  the
cases  of  hospital  acquired  acute  kidney  injury  and  is  the
third  commonest  cause  of  acute  tubular  necrosis  in  patients
admitted  to  hospital,  after  impaired  renal  perfusion  and  the
use  of  nephrotoxic  medication.3 Up  to  10%  may  need  tem-
porary  dialysis.  Patients  with  severe  kidney  disease  prior  to
contrast  administration  may  progress  to  end-stage  kidney
disease.  Its  occurrence  is  associated  with  increased  risk  of
complications  and  death  on  short-4,5 and  long-term5--7 and
leads  to  extended  hospital  stay4,5,8,9 as  well  as  to  increased
health-care  costs.5
As  the  number  of  diagnostic  and  interventional  angiogra-
phies  and  CT  examinations  increases  in  clinical  practice
and  higher  doses  of  contrast  media  are  administered  to
sicker  and  older  patients,  CI-AKI  is  an  increasing  problem.2 It
remains  one  of  the  most  clinically  important  complications
of  the  use  of  iodinated  contrast  media.6,10
CI-AKI  is  unique  is  that  its  risk  factors  are  known,  it  is
universally  iatrogenic  and  its  timing  is  predictable.  Also,
in  virtue  of  the  elective  nature  of  most  of  the  radiologic
procedures  that  require  iodinated  contrast  administra-
tion,  contrast  nephropathy  is  probably  one  of  the  few
preventable  forms  of  AKI  and  a  condition  for  which
standardized  preventive  strategies  would  be  feasible  and
effective.11
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everal  articles  were  searched  in  nephrology  journals
‘‘American  Journal  of  Kidney  Disease’’,  ‘‘Journal  of  the
merican  Society  of  Nephrology’’,  ‘‘Clinical  Journal  of  the
merican  Society  of  Nephrology’’,  ‘‘Kidney  International’’
nd  ‘‘Nephrology  Dialysis  Transplantation’’)  for  a  global
iew  on  contrast-induced  acute  kidney  injury  and  prophylac-
ic  strategies.  Subsequently,  individual  searches  were  made
n  MEDLINE® database  for  randomized  controlled  trials  and
eta-analyses  on  each  prophylactic  strategy  encountered.
eﬁnition
I-AKI  is  the  acute  deterioration  of  renal  function  after
arenteral  administration  of  radiocontrast  media  that  can-
ot  be  attributed  to  other  causes.  The  diagnosis  of  CI-AKI
equires  an  absolute  or  relative  increase  in  serum  creatinine
SCr),  temporally  related  to  the  parenteral  administration  of
he  contrast  agent  and  exclusion  of  alternative  explanations
or  renal  impairment.1 The  most  common  deﬁnition  used  in
pidemiologic  studies6 and  clinical  trials10 is  an  increase  in
Cr  ≥  0.5  mg/dL  or  ≥25%  above  baseline  within  24  to  72  h
fter  contrast  administration.  Despite  the  recent  deﬁnitionroup,  that  is  an  increase  in  SCr  ≥  0.3  mg/dL  within  48  h,
ost  studies  continue  to  use  the  former  deﬁnition  of  CI-
KI.66,71,72
7 R.  Gouveia  et  al.
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Table  1  Risk  factors  for  CI-AKI.
Risk  factor  Odds  ratio  (95%  CI)
Patient  related
Pre-existing  impairment
in kidney  function
Baseline  serum
creatinine
1.2--1.9  mg/dL  2.42  (1.54--3.79)a
2.0--2.9  mg/dL  7.37  (4.78--11.39)a
>3.2  mg/dL  12.82  (8.01--20.54)a
Diabetes  mellitus  3.4  (1.8--6.5)b
Hematocrit  <36.8%  2.28  (1.71--3.04)c
Intra-aortic  balloon  pump 2.05  (1.47--2.87)d
Acute  coronary  syndrome  1.85  (1.31--2.63)a
Peripheral  vascular
disease
1.71  (1.23--2.37)a
Congestive  heart  failure  1.53  (1.12--2.1)a
Arterial  hypertension  1.45  (1.24--1.71)d
Exposure  to  ACEi  and  ARB  1.43  (10.6--1.94)e
Pre-procedure  shock  1.19  (0.72--1.96)a
Age  (1-year  increment)  1.02  (1.01--1.03)a
Exposure  to  nephrotoxins  NA
Hypovolemia  NA
Procedure  related
Ionic  contrast  media  (in
high-risk  patients)
3.3  (1.6--6.6)b
Volume  of  contrast  media
(per  100  mL  increment)
1.12  (1.02--1.23)a
Intra-arterial
administration  of
contrast  media
NA
CI, conﬁdence interval; ACEi, angiotensin-converting-enzyme
inhibitors; ARB, angiotensin receptor blocker; NA, non-available
data.
a Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic
importance of acute renal failure after percutaneous coronary
intervention. Circulation. 2002;105(19):2259--64.
b Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of
ionic and nonionic contrast media in 1196 patients: a randomized
trial. Iohexol Cooper Study Kidney Int. 1995;47(1):254--61.
c Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit pre-
dicts contrast-induced nephropathy after percutaneous coronary
interventions. Kidney Int. 2005 February;67(2):706--13.
d Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for
prediction of contrast-induced nephropathy after percutaneous
coronary intervention: development and initial validation. J Am
Coll Cardiol. 2004 October;44(7):1393--9.
e Rim MY, Ro H, Kang WC,  et al. The effect of renin-
angiotensin-aldosterone system blockade on contrast-induced
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pidemiology/risk factors
he  reported  incidence  of  CI-AKI  varies  widely  depending
n  the  deﬁnition  used,  the  presence  of  risk  factors,  espe-
ially  chronic  kidney  disease  and  diabetes  mellitus,  and  the
mount  and  type  of  contrast  media  administered.  Among
atients  with  no  risk  factors  for  CI-AKI,  namely  chronic
idney  disease,  the  risk  is  negligible.12 Among  high-risk
atients,  the  reported  risk  following  percutaneous  angiog-
aphy  is  10--30%.2,6,10,12,13
The  most  important  risk  factor  for  CI-AKI  is  pre-existing
mpairment  of  kidney  function.  The  magnitude  of  the  risk  is
irectly  associated  with  the  severity  of  renal  dysfunction6
nd  is  potentiated  by  the  association  with  diabetes  melli-
us  and  with  other  risk  factors.  Isolated  diabetes  mellitus,
ithout  concurrent  kidney  dysfunction,  does  not  appear
o  be  a  signiﬁcant  risk  factor,  acting  instead  as  a  risk
ultiplier.1,6,12--14 Additional  risk  factors  for  CI-AKI,  as  listed
n  Table  1,  include  increasing  age,  arterial  hypertension,
eripheral  vascular  disease,  congestive  heart  failure,  acute
oronary  syndrome,  pre-procedure  shock  and  the  use  of
ntra-aortic  balloon  pump.6,15 A  low  baseline  hematocrit
as  also  identiﬁed  as  an  independent  predictor  of  CI-
KI.16 The  use  of  drugs  affecting  kidney  auto-regulation,
amely  angiotensin-converting-enzyme  inhibitors  (ACEi)
r  angiotensin  receptor  blockers  (ARB),  has  also  been
ssociated  with  an  increased  risk  of  CI-AKI.17 As  for
ther  causes  of  acute  kidney  injury,  hypovolemia  and
xposure  to  nephrotoxic  drugs,  including  non-steroidal  anti-
nﬂammatory  drugs,  aminoglycosides  and  amphotericin  B
mong  others,  increase  the  risk  of  CI-AKI.  Kidney  transplant
atients  are  also  at  an  increased  risk  of  CI-AKI  because  of  the
igh  prevalence  of  diabetes,  hypertension,  graft  dysfunc-
ion  and  the  concurrent  use  of  nephrotoxic  drugs,  namely
alcineurin  inhibitors.1
The  type  of  radiologic  procedure  also  inﬂuences  the  risk
f  CI-AKI.  Among  all  procedures  that  require  contrast  media
dministration,  diagnostic  and  interventional  coronary  and
eripheral  angiography  is  associated  with  the  highest  risk
f  CI-AKI.  This  probably  results  from  a  high  volume  of
ontrast  and  from  its  intra-arterial  administration  which
s  associated  with  higher  acute  intrarenal  concentration.
oreover,  advanced  vascular  disease,  which  is  usually  asso-
iated  with  diabetes  and  hypertension,  and  hemodynamic
nstability  are  more  frequent  in  patients  undergoing  coro-
ary  angiography.18
linical presentation
he  clinical  presentation  of  CI-AKI  involves  an  asymptomatic
ncrease  in  SCr  occurring  within  24--72  h  of  intravascular
odinated  contrast  administration,  peaking  on  the  third  to
fth  days.  In  the  majority  of  patients,  the  transient  rise
n  SCr  is  the  sole  manifestation  of  CI-AKI.  Nevertheless,  a
mall  proportion  of  patients  can  present  with  oliguria  and
ther  complications  of  AKI,  namely  hyperkalemia,  metabolic
cidosis  and  uremic  syndrome.4,19 Once  CI-AKI  is  estab-
ished,  renal  function  remains  depressed  for  1--3  weeks  in
ost  cases.20 About  6--10%  of  CI-AKI  patients  require  renal
eplacement  therapy  in  the  acute  phase.6,13,19 Spontaneous
ecovery  of  renal  function  is  to  be  expected.  Occasionally,
D
A
eacute kidney injury: a propensity-matched study. Am J Kidney
Dis. 2012;60:576.
enal  failure  is  irreversible  and  thus  requires  long-term  dial-
sis,  especially  in  those  patients  with  baseline  severe  kidney
ysfunction.19ifferential diagnosis
s  previously  stated,  the  diagnosis  of  CI-AKI  requires  the
xclusion  of  other  causes  of  AKI,  namely  pre-renal  azotemia
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Table  2  Tested  strategies  in  the  prevention  of  CI-AKI  in
high-risk  patients.
Strategies  with  proven  beneﬁt
Use of  non-ionic  contrast  media
IV  volume  expansion  with  isotonic  ﬂuid
Strategies  with  potential  beneﬁt,  requiring  further  study
Oral  n-acetylcystein
Statins
Iloprost
Sodium  citrate
Trimetazidine
Strategies  that  proved  no  beneﬁt
Diuretics  (furosemide,  mannitol)
Theophylline
Fenoldopam
Non-selective  endothelin  receptor  antagonist
Anaritide
Table  3  Types  of  iodinated  contrast  agents.
High-osmolar  (1400--1800  mosmol/kg)/Ionic
• Diatrizoate  (Hypaque®,  Gastrograﬁn®,  Urograﬁn®)
Low-osmolar  (500--850  mosmol/kg)
Ionic
• Ioxaglate  (Hexabrix®)
Non-ionic
• Iohexol  (Omnipaque®)
• Iopamidol  (Isovue®,  Iopamiro®,  Iopamiron®,  Niopam®)
• Iopromide  (Ultravist®)
• Ioversol  (Optiray®)
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or  ischemic  acute  tubular  necrosis,  acute  interstitial  nephri-
tis  and  renal  atheroemboli.5 The  history  of  additional  insults
such  as  sepsis,  hypotension  and  exposure  to  nephrotoxic
drugs  suggests  the  possibility  of  the  ﬁrst  two  diagnoses.
Renal  atheroemboli  should  be  suspected  after  angiogra-
phy  in  the  presence  of  digital  ischemia,  livedo  reticularis,
eosinophilia,  hypocomplementemia,  when  the  onset  of  AKI
is  delayed  for  several  days  after  the  procedure  and  in  the
absence  of  improvement  of  kidney  function  in  patients  with
diffuse  vascular  disease  subjected  to  intra-arterial  contrast
administration  and  interventional  procedures.21
Pathophysiology
The  pathophysiology  of  contrast-induced  nephropathy  is
still  a  matter  of  debate.  Among  the  mechanisms  proposed
are  altered  renal  hemodynamics  with  intrarenal  vasocon-
striction  contributing  to  medullary  hypoxia  and  direct
cytotoxicity  of  radiocontrast  not  only  to  tubular  cells  but
also  to  endothelial  cells.  Some  mediators  of  injury  are  pos-
sibly  endothelin,  reactive  oxygen  species  and  adenosine.  It
is  also  hypothesized  that  the  high  viscosity  of  iso-osmolar
contrast  media  can  aggravate  medullary  hypoxia  not  only  by
the  impairment  of  medullary  blood  ﬂow  but  also  by  increas-
ing  tubular  ﬂuid  viscosity  and  the  intratubular  resistance  to
ﬂow.  Probably  all  these  mechanisms  act  in  concert  to  cause
CI-AKI.11,20,22
Prevention
In  the  absence  of  effective  therapy  and  especially  for
iatrogenic  diseases,  prevention  should  always  be  the  high-
est  priority.  Several  approaches  to  CI-AKI  prevention  have
been  reported  (Table  2),  of  which  vigorous  hydration  and
the  use  of  non-ionic  contrast  media  are  the  most  impor-
tant  and  widely  accepted.20 The  use  of  prophylactic  oral
N-acetylcysteine  is  also  a  popular  strategy  in  high-risk
patients.  Many  drugs  and  strategies  have  been  tested  in  the
d
c
p
nIso-osmolar  (∼290  mosmol/kg)/Non-ionic
• Iodixanol  (Visipaque®)
revention  of  CI-AKI,  with  disappointing  results.23--29,38 Other
trategies  require  further  study.30,31
he choice of the contrast agent
ypes  of  contrast  agent  (Table  3)
ince  the  1950s,  the  available  contrast  media  have  been
ased  on  triiodobenzene.20 They  are  commonly  grouped
ccording  to  their  ionicity  and  osmolality.  The  ﬁrst  contrast
edia  to  be  developed  was  ionic  and  high-osmolar.  Latter
ere  developed  the  low-  and  iso-osmolar  contrast  media
hich  are  non-ionic,  except  for  ioxaglate.2,20 Since  the  intro-
uction  of  non-ionic  contrast  media,  the  toxicity  of  these
ompounds  has  been  mainly  attributed  to  their  osmolality,
iscosity  and  chemotoxicity.2
Today  only  low-osmolar  contrast  media  (which  still  have
onsiderably  higher  osmolality  than  plasma)  and  iso-osmolar
ontrast  media  are  widespread  because  of  the  fewer  adverse
ffects  compared  to  high-osmolar  contrast  media,2 espe-
ially  in  high-risk  patients  with  an  elevated  pre-procedural
erum  creatinine.2,12,20
vidence
he  best  data  on  the  beneﬁt  of  non-ionic  contrast  agents
ver  high-osmolar,  ionic  ones  comes  from  the  iohexol  coop-
rative  study.12 This  was  a  large  multicenter  double-blind
andomized  controlled  trial  (RCT)  which  demonstrated  that
he  use  of  the  non-ionic  contrast  agent  iohexol  is  asso-
iated  with  signiﬁcant  less  nephrotoxicity  than  the  ionic
ontrast  agent  diatrizoate  in  patients  with  pre-existing  renal
ailure  alone  or  combined  with  diabetes  mellitus  undergo-
ng  elective  coronary  angiography.  Patients  with  baseline
Cr  ≥  1.5  mg/dL  who  received  diatrizoate  were  3.3  times
ore  likely  to  develop  nephrotoxicity  compared  to  patients
ho  received  iohexol.  In  patients  with  normal  baseline
idney  function  there  was  no  evidence  of  reduced  nep-
rotoxicity  of  the  non-ionic  agent  iohexol  compared  to
iatrizoate.
The  NEPHRIC  study10 reported  a  signiﬁcantly  lower  inci-
ence  of  CI-AKI  with  the  use  of  the  iodixanol  iso-osmolar
ontrast  media  when  compared  to  iohexol  (low-osmolar)  in
atients  with  SCr  1.3--1.5  mg/dL  undergoing  elective  coro-
ary  or  aorto-femural  angiography.  The  better  proﬁle  of  this
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so-osmolar  contrast  media  was  conﬁrmed  in  the  RECOVER
rial,13 when  compared  to  ioxaglate,  an  ionic,  dimeric
ow-osmolar  contrast  agent.  Nevertheless,  subsequent  tri-
ls  comparing  the  use  of  iodixanol  to  other  low-osmolar
ontrast  agents  (iopamidol14,32 and  ioversol33)  showed  no  sig-
iﬁcant  difference  in  the  incidence  of  CI-AKI  in  patients  with
hronic  kidney  disease  undergoing  elective  coronariography
ith  or  without  intervention.  Low-osmolality  contrast  media
eem  to  have  different  renal  safety  proﬁles.  Iopamidol  and
oversol  appear  to  be  as  safe  as  the  iso-osmolar  contrast
odixanol.  On  the  contrary,  iohexol  carries  a  higher  risk  of
I-AKI.  This  fact  argues  against  the  concept  that  osmolal-
ty  is  the  primary  determinant  of  renal  toxicity,  at  least  for
ow-osmolality  contrast  media.
onclusion
n  low-risk  patients,  mainly  the  ones  with  normal  kidney
unction,  the  risk  of  CI-AKI  remains  low  regardless  of  the
ontrast  media  used.  In  patients  at  high  risk  of  CI-AKI,  a  non-
onic  contrast,  either  low-  or  iso-osmolar,  should  be  used  in
he  lowest  possible  dose.
ydration
ational
he  precise  mechanisms  by  which  volume  expansion  pro-
ects  against  CI-AKI  are  unknown.  It  is  speculated  that
olume  expansion  may  act  by  counterbalancing  the  ischemic
ffect  of  radiocontrast  on  medullary  cells.  Dilution  of
he  contrast  media,  particularly  in  the  medullary  tubular
egments,  may  also  reduce  direct  cellular  damage.  The
ncreased  tubular  ﬂuid  viscosity,  induced  by  the  contrast
gent,  is  reduced  by  intravascular  volume  expansion.11,20
he  hypothesis  that  the  alkalinization  of  the  tubular  ﬂuid
an  reduce  the  formation  of  deleterious  hydroxyl  radicals
nd,  hence,  protect  the  renal  medulla  from  oxidative  stress
njury  has  prompted  the  use  of  sodium  bicarbonate  in  the
revention  of  CI-AKI.
vidence
arly  data  on  the  beneﬁt  of  volume  expansion  in  the  pre-
ention  of  CI-AKI  come  from  observational,  uncontrolled
tudies.11,34,35
A  series  of  RCTs,  mostly  in  high-risk  patients  undergoing
lective  or  emergency  coronariography,  either  diagnostic  or
nterventional,  have  been  undertaken  to  study  the  impact  of
ntravenous  ﬂuid  composition,  rate  and  duration  of  adminis-
ration  on  the  prevention  of  CI-AKI.  Most  of  these  trials  are
mall  and  underpowered.
Concerning  the  relative  beneﬁt  of  the  use  of  isotonic
NaCl  0.9%)  versus  hypotonic  sodium  chloride  (NaCl  0.45%)
olutions,  Muller  et  al.8 showed  a  smaller  incidence  of  CI-
KI  with  the  use  of  NaCl  0.9%  (0.7%  versus  2%,  p  =  0.04)  in RCT  enrolling  1620  patients.  The  beneﬁt  was  more  pro-
ounced  in  diabetic  patients  and  in  those  given  >250  mL  of
ontrast.  Despite  the  large  number  of  patients  enrolled  in
his  study,  most  of  the  patients  had  normal  baseline  kidney
i
c
o
pR.  Gouveia  et  al.
unction.  In  the  small  sub-group  of  patients  with  baseline
Cr  >  1.6  m/dL  there  was  no  difference  in  the  incidence  of
I-AKI  in  both  study  arms.  Moreover,  vascular  complications,
eed  for  dialysis,  length  of  hospital  stay,  and  mortality  rates
ere  comparable  between  the  two  groups.
Knasuski  et  al.36 compared  the  use  of  a  short  intra-
enous  hydration  regimen  with  isotonic  saline  (20  min  pre-
hrough  12  h  post-procedure)  with  a  longer  one  using  hypo-
onic  saline  in  5%  dextrose  (at  least  12  h  pre-  and  12  h
ost-procedure)  in  chronic  kidney  disease  patients.  The  inci-
ence  of  CI-AKI  in  the  shorter  regimen  was  10.8%  compared
o  0%  in  the  control  arm  (p  =  0.136).  The  small  number  of
atients  (n  =  63)  and  lack  of  comparability  between  the  two
rms  in  the  volume  and  composition  of  intravenous  ﬂuid
dministered  limit  the  study’s  conclusion  on  the  indepen-
ent  effect  of  timing  and  duration  of  therapy.  Despite  these
imitations,  these  and  the  ﬁndings  of  Bader  et  al.37 in  a  small
imilar  study  suggest  that  the  administration  of  intravenous
uid  over  a sustained  period  of  time  may  be  more  protective
han  bolus  ﬂuid  supplementation.
The  results  from  some  clinical  trials  comparing  volume
xpansion  with  either  isotonic  NaHCO3 or  isotonic  saline
ave  suggested  the  protective  role  of  NaHCO3 in  patients
ndergoing  elective9,38 and  emergent39 coronary  angiogra-
hy,  while  others  have  shown  no  beneﬁt.40--42 Moreover,
eta-analyses  of  trials  on  this  matter  have  also  yielded
onﬂicting  results.43--46 One  of  these  meta-analyses45 found
hat  bicarbonate  therapy  was  most  effective  in  coronary
rocedures,  especially  when  emergent,  and  in  patients
ith  chronic  kidney  disease.  Despite  the  heterogeneity  of
esults  relating  to  the  prevention  of  CI-AKI,  it  is  consen-
ual  across  the  studies  that  the  need  for  renal  replacement
herapy43,44,46 and  mortality43,46 does  not  signiﬁcantly  differ
y  ﬂuid  type.  There  is  also  no  difference  in  the  incidence
f  worsening  heart  failure  or  pulmonary  edema  with  sodium
icarbonate  in  comparison  to  normal  saline.43
With  the  increasing  number  of  patients  undergoing  pro-
edures  that  require  iodinated  contrast  administration  on  an
utpatient  base,  the  effectiveness  of  oral  hydration  or  salt
oading  in  the  prevention  of  CI-AKI  has  also  been  tested.
 small  RCT  comparing  the  effect  of  unrestricted  oral  ﬂu-
ds  to  intravenous  isotonic  saline  found  a  higher  incidence
f  AKI  in  the  former  group.47 In  a  subsequent  RCT  enrolling
12  patients  with  stage  3 chronic  kidney  disease,  oral  saline
ydration  (1  g/10  kg  of  body  weight  of  NaCl  per  os  for  2
ays  before  the  procedure)  was  as  efﬁcient  as  intravenous
aline  hydration  for  the  prevention  of  CI-AKI.48 Given  the
imited  data,  the  safety  and  efﬁcacy  of  oral  hydration  and
alt  loading  remain  uncertain  in  the  prevention  of  CI-AKI.
onclusion
n  conclusion,  it  is  generally  accepted  that  volume  expan-
ion  reduces  the  risk  of  CI-AKI  and  that  isotonic  intravenous
uids  offer  greater  beneﬁt  than  hypotonic  ﬂuid.  Data  sug-
est  that  isotonic  NaHCO3 is  not  inferior  to  isotonic  saline
nd  may  even  provide  additional  protection  against  CI-AKI
n  chronic  kidney  disease  patients  undergoing  coronary  pro-
edures.  Moreover,  its  infusion  over  a  relatively  short  period
f  time  before  and  after  contrast  administration  is  safe  and
ossibly  effective.  Additional  studies  are  warranted  before
 pro
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pContrast-induced  acute  kidney  injury  --  A  review  focusing  on
abbreviated  bicarbonate  intravenous  ﬂuid  regimens  become
the  standard  of  care.11 There  remains  a  clear  need  for  well-
powered  studies  with  large  numbers  of  high-risk  patients
to  answer  the  questions  of  composition,  route  of  adminis-
tration,  rate  and  duration  of  volume  expansion  to  prevent
CI-AKI.11
The  selection  of  ﬂuid  and  rate  of  administration  must
take  into  account  the  patient’s  ability  to  tolerate  the  ﬂuid
load  and  the  underlying  risk  for  nephropathy.  A  possible
approach  is  the  administration  of  either  isotonic  ﬂuid  at
a  rate  of  1  mL/kg/h  for  12  h  before  and  after  contrast
administration  in  high-risk  hospitalized  patients  undergoing
elective  procedures.  An  alternative  for  patients  undergoing
urgent  procedures  or  for  whom  sustained  volume  expansion
is  not  possible  is  an  abbreviated  regimen  of  isotonic  ﬂuid  at
3  mL/kg/h  1  h  before  and  until  6  h  after  the  procedure.11
N-acetylcysteine
Rational
As  the  increased  oxidative  stress  seems  to  have  a  role
in  the  pathogenesis  of  CI-AKI  it  seems  reasonable  to  use
anti-oxidants  in  its  prevention.  N-acetylcysteine  (NAC)  may
prevent  CI-AKI  by  stopping  direct  oxidative  tissue  damage
and  by  improving  renal  hemodynamics.49
Evidence
Similar  to  the  effect  of  different  regimens  of  intravenous
ﬂuid  therapy,  the  relatively  small  RCTs  on  the  effect  of
oral  NAC  in  the  prevention  of  CI-AKI  have  shown  conﬂicting
results.  Some  have  shown  a  reduction  of  the  risk  of  CI-
AKI  in  high-risk  patients49,50 while  others  have  shown  no
beneﬁt  with  the  use  of  NAC.51--53 Most  meta-analyses  of
RCTs  on  this  matter  have  shown  signiﬁcant54--59 or  at  least
a  non-signiﬁcant  trend60 toward  the  beneﬁt  of  the  use  of
NAC  in  association  with  intravenous  volume  expansion  in
the  prevention  of  CI-AKI.  A  ﬁnding  common  to  all  trials
is  the  minimal  toxicity  of  oral  NAC.  Recently,  the  largest
RCT  to  date  comparing  the  renal  outcomes  in  patients
undergoing  coronary  or  peripheral  angiography  receiving
oral  NAC  was  published.  Patients  in  the  study  arm  received
oral  NAC  1200  mg  twice  daily  versus  placebo,  in  associa-
tion  with  intravenous  volume  expansion.  This  trial  included
2308  patients  and  showed  no  beneﬁt  for  NAC.61 However
this  study  had  several  shortcomings:  only  about  a  third  of
the  patients  had  chronic  kidney  disease  (CKD)  deﬁned  as  a
eGFR  less  than  60  mL/min/1.73  m2 and  only  about  16%  had  a
SCr  >  1.5  mg/dL.  Also,  the  incidence  of  CI-AKI  was  low,  even
in  patients  with  SCr  >  1.5  mg/dL  and  over  20%  of  patients
received  high-osmolar  contrast  media.
Trials  have  also  been  undertaken  on  different  NAC  regi-
mens.  Brigori  et  al.62 undertook  a  RCT  comparing  standard
dose  (600  mg  twice  daily)  to  high  dose  oral  NAC  (1200  mg
twice  daily).  They  showed  a  smaller  incidence  of  CI-AKI  with
the  high  dose  regimen  (3.5%  versus  11%,  p  =  0.038).  Also,  a
meta-analysis  on  this  matter,  including  mainly  patients  with
CKD,  showed  an  odds  ratio  of  0.46  for  the  occurrence  of  CI-
AKI  with  the  use  of  high  dose  NAC  deﬁned  as  a  daily  dose
g
b
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uperior  to  1200  mg  or  a  single  pre-procedural  dose  above
00  mg.63
Intravenous  NAC  has  also  been  used  in  patients  requir-
ng  emergent  angiographic  procedures  in  whom  prophylaxis
ith  the  oral  formulation  in  the  day  before  contrast  admin-
stration  is  not  feasible.  As  with  oral  NAC  the  results
ere  discordant.50,64 In  the  positive  study,50 7%  of  the
atients  treated  with  intravenous  NAC  developed  anaphylac-
oid  reactions.  Moreover,  a  recent  meta-analysis  has  shown
o  signiﬁcant  beneﬁt  with  the  use  of  intravenous  NAC.65
onclusion
n  conclusion,  the  use  of  high  dose  oral  NAC  in  the  prevention
f  CI-AKI,  in  association  with  intravenous  volume  expan-
ion,  is  generally  recommended  given  the  possible  beneﬁt,
he  favorable  side-effects  proﬁle,  the  low  cost  and  ease  of
se.  In  contrast,  the  use  of  parenteral  NAC  is  not  recom-
ended,  due  to  not  only  to  the  lack  of  evidence  but  also  to
he  reported  adverse  reactions.
tatins
ational
leiotropic  effects  of  statins  include  improved  endothelial
unction,  reduced  inﬂammatory  and  immune-modulatory
rocesses,  improved  oxidative  stress  and  platelet  adhesion.
tatin  treatment  in  patients  with  coronary/peripheral  artery
isease,  as  recommended  by  current  guidelines,  is  associ-
ted  with  a  lower  incidence  of  major  adverse  cardiac  events
nd  lower  mortality  in  the  short-  and  long-term.66
vidence
he  ﬁrst  evidence  from  the  beneﬁt  of  statins  in  the  preven-
ion  of  CI-AKI  came  from  observational  studies.67,68 RCTs  on
he  effect  of  these  drugs  in  the  prevention  of  CI-AKI  have
gain  shown  conﬂicting  results.  Earlier,  relatively  smaller
tudies  on  this  matter,  in  patients  with  stable  coronary  heart
isease,  did  not  show  a  signiﬁcant  beneﬁt.69,70 In  the  last
ew  years,  larger  RCTs  have  shown  the  possible  beneﬁt  of
tatins.  Two  studies  have  been  undertaken  in  statin-naïve
atients  with  acute  coronary  syndrome  subjected  to  early
ercutaneous  coronary  intervention.71,72 These  studies  have
hown  the  beneﬁt  of  the  pre-procedure  administration  of
igh  doses  of  statins  in  association  with  intravenous  hydra-
ion  when  compared  to  placebo  and  intravenous  hydration
CI-AKI  incidence  5%  versus  13.2%,  p  =  0.04671 and  6.7%  ver-
us  15.1%,  odds  ratio  0.38,  95%  CI  0.2--0.71,  p  =  0.00372).
n  one  study,71 patients  received  80  mg  of  atorvastatin  12  h
efore  plus  40  mg  immediately  before  the  procedure.  In
he  other  study,  40  mg  of  rosuvastatin  was  administered
t  admission  time.72 The  30-day  incidence  of  adverse  car-
iovascular  and  renal  events,  namely  need  for  dialysis  and
ersistent  renal  damage,  was  signiﬁcantly  lower  in  the  statin
roup.72 Patients  with  SCr  >  3  mg/dL  were  excluded  from
oth  studies.
The  largest  RCT  to  date  enrolled  2998  patients  with
iabetes  mellitus  and  chronic  kidney  disease  (creatinine
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learance  between  30  and  89  mL/min/1.73  m2)  undergoing
oronary  or  peripheral  angiography  and  used  standard  doses
f  rosuvastatin.73 Patients  in  the  study  arm  received  a  daily
ose  of  10  mg  of  rosuvastatin  from  2  days  before  until  3
ays  after  contrast  administration.  Three  days  after  the  pro-
edure  both  control  and  study  arms  were  given  a  statin.
ll  patients  received  intravenous  volume  expansion  and  iso-
smolar  contrast  media.  The  incidence  of  CI-AKI  was  lower
n  the  rosuvastatin-treated  group  (2.3  versus  3.9%,  p  =  0.01).
lthough  this  beneﬁt  was  consistently  observed  among  the
arious  subgroups  studied,  it  was  more  signiﬁcant  in  patients
ith  CKD  stage  2.  There  were  no  signiﬁcant  differences  in
ll-cause  deaths  or  need  for  kidney  replacement  therapy.
mportantly,  there  were  no  signiﬁcant  differences  between
he  two  groups  in  rates  of  muscle  pain  and  liver  function
ests.  Recent  meta-analyses74,75 have  also  shown  a  signif-
cant  reduction  in  the  incidence  of  CI-AKI  associated  with
tatin  therapy.
onclusion
t  seems  reasonable  and  safe  to  start  a  statin  prior  to  angi-
graphic  procedures  among  those  patients  who  are  likely  to
e  started  on  such  a  drug  prior  to  discharge,  regardless  of
aseline  kidney  function.  Nevertheless  data  on  CKD  patients
ave  been  conﬂicting  and  exclude  patients  with  CKD  stage
.
emoval of nephrotoxic drugs
otential  nephrotoxic  drugs  should  be  discontinued,  when-
ver  possible,  before  contrast  administration  (aminoglyco-
ides,  vancomycin,  amphotericin  B,  cisplatin,  non-steroidal
nti-inﬂammatory  drugs).
Some  guidelines  suggest  that  metformin  ought  to  be  dis-
ontinued  at  least  12  h  before  contrast  administration  and
ot  be  resumed  for  a  minimum  a  36  h  after  the  procedure.
he  rational  is  that  the  onset  of  CI-AKI  is  quite  rapid  and
etformin  retention  in  this  setting  can  lead  to  lactic  acido-
is.  This  recommendation  is  based  on  observational  studies,
ase  reports  and  case  series.76
The  chronic  use  of  angiotensin-converting-enzyme
nhibitors  (ACEi)  or  angiotensin  receptor  blockers  (ARB)  prior
o  contrast  studies  was  associated  with  a  higher  incidence
f  CI-AKI  in  a  retrospective  study.17 Nevertheless,  a  previ-
us  study  enrolling  220  patients  who  were  on  ACEi  and/or
RB  had  shown  no  beneﬁt  in  the  group  of  patients  in  which
hese  drugs  were  withheld  compared  to  a  control  group  in
hich  these  agents  were  continued.77 Whether  or  not  the
iscontinuation  of  these  drugs  reduced  the  risk  of  CI-AKI  is
till  a  matter  of  debate.  At  present  there  is  insufﬁcient  evi-
ence  to  recommend  discontinuation  of  ACEi  and  ARB  prior
o  contrast  administration.78
xtracorporeal blood puriﬁcationational
odinated  contrast  is  water  soluble  and  freely  ﬁltered  in
he  glomeruli  so  that  its  elimination  is  slower  in  patients
t
i
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ith  chronic  kidney  disease.  It  is  also  efﬁciently  cleared  by
emodialysis  and  to  a  lesser  extent,  hemoﬁltration.79 There-
ore  it  could  be  that  removal  of  contrast  media  immediately
fter  the  procedure  could  effectively  prevent  CI-AKI.
vidence
CTs  enrolling  patients  with  variable  degrees  of  CKD  sched-
led  for  coronary  angiography  have  shown  a  reduction  of
he  incidence  of  CI-AKI  in  those  submitted  to  pre-  and  post-
rocedure  hemoﬁltration80,81 or  hemodialysis.82 Clinically
eaningful  outcomes  as  need  for  renal  replacement  ther-
py  (RRT)  due  to  oliguria,80,82 in-hospital  mortality,80 need
or  chronic  dialysis80,82 and  mortality  at  1  year80 were  sig-
iﬁcantly  better  in  the  hemoﬁltration80/hemodialysis82 arm
ompared  with  intravenous  volume  expansion  in  the  con-
rol  arm.  However,  both  of  these  trials  were  not  blinded
nd  patients  in  the  RRT  group  were  admitted  to  an  intensive
are  unit  whereas  patients  in  the  control  arm  were  in  a  step
own-unit,  with  a  less  intensive  care.  Creatinine  removal  by
he  procedure  can  also  explain  some  of  the  early  differences
n  outcomes.  Moreover,  one  trial81 comparing  the  effect  of
ntravenous  volume  expansion  alone  versus  hemoﬁltration
nly  after  the  procedure  versus  hemoﬁltration  done  before
nd  after  contrast  administration  showed  that  it  is  necessary
or  patients  to  undergo  hemoﬁltration  before  the  procedure
o  obtain  the  full  clinical  beneﬁt.  This  suggests  that  more
mportant  than  contrast  removal  by  RRT,  high-volume  con-
rolled  hydration  before  contrast  media  exposure  may  play
 major  role  in  preventing  CI-AKI.
Despite  the  beneﬁts  observed  in  these  trials,  meta-
nalyses  have  shown  no  beneﬁt  of  RRT  in  the  prevention
f  CI-AKI.  Moreover,  if  we  limit  the  analysis  to  studies  of
emodialysis,  it  is  associated  with  an  increase  in  the  risk  of
I-AKI.83
There  is  no  evidence  that  hemodialysis  immediately  after
ntravascular  contrast  administration  prevents  volume  over-
oad  or  decline  of  residual  renal  function  in  stage  5d  CKD
atients.84--86
onclusion
he  only  studies  we  have  available  are  small  and  ﬂawed.
oreover  meta-analyses  have  shown  no  beneﬁt  or  even  harm
n  the  use  of  RRT  for  the  prevention  of  CI-AKI.  Therefore  this
s  not  a  recommended  strategy  for  the  prevention  of  CI-AKI.
In  stage  5  CKD  patients  on  hemodialysis,  there  is  no
vidence  of  the  beneﬁt  of  immediate  dialysis  after  intravas-
ular  contrast  administration.
onclusion
I-AKI  is  a  frequent  cause  of  intrahospital  acute  kid-
ey  injury  and  one  of  the  most  common  complications
f  iodinated  contrast  administration.  The  most  important
isk  factors  for  CI-AKI  are  pre-existing  kidney  dysfunc-
ion,  particularly  in  association  with  diabetes  mellitus  and
ntravascular  volume  depletion.  As  for  most  forms  of  AKI
here  is  no  speciﬁc  treatment  once  it  is  established.  Never-
heless  it  is  one  of  the  few  predictable  forms  of  AKI,  giving
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Assess CI-AKI risk 
• Baseline kidney dysfunction
• Diabetes mellitus
• Intra-arterial contrast administration   
eGFR >60mL/min/m2 eGFR 30-60mL/min/m2 eGFR <30mL/min/m2
•  Avoid dehydration
•  No need for specific
   prophylactic measures   
•  Use non-ionic contrast media
•  Use a low volume of contrast
•  IV volume expansion
•  Oral NAC 1200mg bid
•  Consider statin
•  Monitor serum creatinine and
   potassium
•  Discontinue
 o Nephrotoxic drugs
 o Metformin
 o ACEi and ARBs          
•  As for eGFR 30-
   60mL/min/1.73m2
•  Monitor diuresis
•  Nephrology consultation  
IV volume expansion 
NaCl 0.9% at 1mL/Kg/h for 12 hours pre and 12 hours post contrast administration
For same day procedures:
 
Isotonic NaCl or NaHCO3  at 3mL/Kg/h for 1-3 hours pre and 6 hours post contrast administration
Monitor for signs of volume overload 
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us  a  unique  opportunity  for  identiﬁcation  of  patients  at  high-
risk  and  institution  of  prophylactic  interventions.  Most  trials
addressing  prophylactic  strategies  for  CI-AKI  enroll  patients
subjected  to  intra-arterial  administration  of  iodinated  con-
trast  media,  usually  for  coronary  or  peripheral  angiography.
The  use  of  non-ionic  iodinated  contrast  media,  either  low-
or  iso-osmolar,  seems  to  reduce  the  risk  of  CI-AKI.  Innumer-
ous  pharmacological  and  non-pharmacological  interventions
have  been  tested,  of  which  the  most  successful  and  widely
accepted  is  volume  expansion  with  intravenous  isotonic  ﬂu-
ids,  either  isotonic  saline  or  isotonic  sodium  bicarbonate.
Also,  oral  NAC  is  frequently  used  in  the  prevention  of  CI-AKI
based  on  its  possible  beneﬁt  and  favorable  side  effects  pro-
ﬁle.  Recently,  some  studies  have  also  shown  the  beneﬁt  of
the  pre-treatment  with  statins.Based  on  the  available  evidence,  the  authors  present  a
practical  approach  to  the  prevention  of  CI-AKI  in  Fig.  1.
First,  the  risk  of  CI-AKI  should  be  assessed,  based  on
the  presence  and  combination  of  the  most  important  risk for  CI-AKI  prevention.
actors,  namely  baseline  kidney  function,  diabetes  mellitus
nd  the  type  of  procedure  scheduled.  High-risk  patients,
hat  is  those  with  baseline  estimated  glomerular  ﬁltration
ate  <60  mL/min/1.73  m2, should  be  subjected  to  prophylac-
ic  measures  of  which  the  most  important  are  intravenous
ydration  and  oral  N-acetylcysteine.  Also  the  lowest  possible
ose  of  non-ionic  contrast  media  should  be  administered.
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